文献速递前列腺癌

接受根治性放疗联合或不联合雄激素剥夺治疗的前列腺癌男性患者卒中与血栓栓塞事件

Stroke and thromboembolic events in men with prostate cancer treated with definitive radiation therapy with or without androgen deprivation therapy.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2019-04-15

该观察性队列研究纳入美国退伍军人事务部2001年1月1日至2015年10月31日诊断并接受根治性放疗的前列腺癌患者44246例,中位随访6.8年。多变量竞争风险模型显示,雄激素剥夺治疗(ADT)与卒中(SHR=1.19,95%CI=1.09-1.30,p<0.01)、短暂性脑缺血发作(TIA;SHR=1.24,95%CI=1.08-1.41,p<0.01)和深静脉血栓(DVT;SHR=1.18,95%CI=1.04-1.34,p<0.01)风险升高相关;仅在接受ADT超过1年的男性中,ADT与肺栓塞(PE)相关(SHR=1.34,95%CI=1.06-1.69,p=0.03)。

要点

  • 接受ADT的前列腺癌根治性放疗患者卒中、TIA和DVT风险升高。
  • ADT超过1年者肺栓塞风险升高,SHR=1.34(95%CI=1.06-1.69)。
  • 10年卒中、TIA、DVT、PE累积发生率分别为6.0%、3.0%、3.4%、1.9%。

核心结论

  • 接受ADT的男性中观察到卒中、TIA和DVT风险增加,接受长期ADT的男性中观察到PE风险增加。
  • 这些结果凸显了ADT治疗前列腺癌时对卒中与血栓栓塞事件长期风险的担忧。

研究设计与样本

  • 观察性队列研究,纳入2001年1月1日至2015年10月31日在美国退伍军人事务部诊断并接受根治性放疗的前列腺癌患者。
  • 暴露定义为前列腺癌诊断后1年内开始ADT。
  • 主要结局为卒中、TIA、DVT或PE的发生。
  • 共纳入44246名男性,中位随访6.8年。

主要发现

  • 10年时卒中、TIA、DVT和PE的总体累积发生率分别为6.0%、3.0%、3.4%和1.9%。
  • 多变量竞争风险模型中,ADT与卒中显著相关(SHR=1.19,95%CI=1.09-1.30,p<0.01)。
  • ADT与TIA显著相关(SHR=1.24,95%CI=1.08-1.41,p<0.01)。
  • ADT与DVT显著相关(SHR=1.18,95%CI=1.04-1.34,p<0.01)。
  • 仅在接受ADT超过1年的男性中,ADT与PE相关(SHR=1.34,95%CI=1.06-1.69,p=0.03)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is conflicting evidence regarding the association between androgen deprivation therapy (ADT) for prostate cancer (PC) and the risk of developing stroke and thromboembolic events. Our study evaluated the association between ADT use and development of stroke, transient ischemic attack (TIA), deep vein thrombosis (DVT), and pulmonary embolism (PE) in a homogenous group of men with PC treated with definitive radiation therapy (RT) after controlling for multiple sources of confounding. METHODS: Observational cohort study of patients diagnosed with PC at the US Department of Veterans Affairs between 1 January 2001 and October 31, 2015 and treated with definitive RT. Exposure was initiation of ADT within 1 year of PC diagnosis. Primary outcomes were development of stroke, TIA, DVT, or PE. RESULTS: 44,246 men with median follow-up of 6.8 years. The overall cumulative incidences of stroke, TIA, DVT, and PE at 10 years were 6.0, 3.0, 3.4, and 1.9%, respectively. In the multivariable competing risks model, there was a significant association between ADT and stroke (subdistribution hazard ratio (SHR) = 1.19, 95% CI = 1.09-1.30, p < 0.01), TIA (SHR = 1.24, 95% CI = 1.08-1.41, p < 0.01), and DVT (SHR = 1.18, 95% CI = 1.04-1.34, p < 0.01). ADT was only associated with PE in men receiving ADT for > 1 year (SHR = 1.34, 95% CI = 1.06-1.69, p-value = 0.03). CONCLUSION: We observed an increase in the risk of stroke, TIA, and DVT in men receiving ADT and an increased risk of PE in men receiving long-term ADT. These results highlight concerns regarding long-term risks of ADT on stroke and thromboembolic events in the treatment of PC.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Deka R, Simpson DR, Panizzon MS, et al. Stroke and thromboembolic events in men with prostate cancer treated with definitive radiation therapy with or without androgen deprivation therapy. Prostate Cancer Prostatic Dis. 2019. PMID: 30988408. doi:10.1038/s41391-019-0150-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。